Amicogen (092040) Fundamentals 2026 — Revenue Analysis | SniperIQ
Amicogen (092040) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩66.6B, trading at ₩1170.00 on the KOE. This SniperIQ fundamentals page covers Amicogen's valuation, profitability (net margin -10.5%), revenue (₩42.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Amicogen's market cap?
Amicogen (092040) has a market capitalization of approximately ₩66.6B, trading at ₩1170.00 on the KOE. Market cap moves with the live share price.
What is Amicogen's P/E ratio?
Amicogen's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Amicogen?
Amicogen runs a net profit margin of -10.5%, a gross margin of 12.2%, and an operating margin of -32.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Amicogen generate?
Amicogen reported revenue of ₩42.0B for fiscal year 2025, with net income of -₩30.0B and earnings per share (EPS) of -540.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Amicogen pay a dividend?
Amicogen does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Amicogen financially healthy?
Amicogen carries a debt-to-equity ratio of 0.47x and a current ratio of 1.07x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Amicogen a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amicogen (092040) the key facts are: market cap ₩66.6B, revenue ₩42.0B, 52-week range 1104-4400. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Amicogen's full fundamentals live
Get Amicogen's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.